News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Jeanne Linke Northrop

Advertisement

Articles by Jeanne Linke Northrop

Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics

Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

ByJeanne Linke Northrop
June 13th 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Advertisement

Latest Updated Articles

  • Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics
    Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

    Published: June 13th 2024 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics

2

AstraZeneca to Announce Deal with Trump Administration: Report

3

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

4

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

5

Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us